TriSalus Life Sciences, Inc. announced that it will receive $50 million in a round of funding on April 30, 2024. The transaction will include participation from new investor OrbiMed Advisors LLC. The company has signed the Credit Agreement.

The company issued $25 million in its first tranche. In addition, an aggregate of up to an additional $25 million is available in two tranches at the company?s option, based on the achievement of certain revenue thresholds. The credit agreement has a five-year term that matures in April 2029.

In connection with the funding of the closing amount, the company also issued OrbiMed Advisors LLC a warrant to purchase 130,805 shares of the Company?s common stock, with an exercise price of $9.5562.